Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
- PMID: 28699650
- PMCID: PMC5591068
- DOI: 10.1111/bjh.14830
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
Abstract
The significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above the upper limit of normal (ULN) with disease characteristics and outcome. Four hundred and nine patients had an LDH above ULN, representing 40% of the study population. Patients with an elevated LDH were older, were less likely to be male and had more extensive organ involvement compared to patients with a normal LDH. Patients with high LDH had greater cardiac and renal dysfunction. Elevated LDH was an independent prognostic marker for overall survival and for death within 6 months of diagnosis, but this was restricted to patients not eligible for stem cell transplant. Serum LDH may act as a marker for organ damage and should be explored as a potential marker for tissue healing and organ recovery.
Keywords: damage; early death; lactate dehydrogenase; prognosis; tissue.
© 2017 John Wiley & Sons Ltd.
Figures
Comment in
-
Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected?Br J Haematol. 2017 Sep;178(6):833-835. doi: 10.1111/bjh.14835. Epub 2017 Jul 24. Br J Haematol. 2017. PMID: 28737209 No abstract available.
Similar articles
-
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.J Clin Oncol. 2012 Sep 20;30(27):3402-7. doi: 10.1200/JCO.2011.40.9631. Epub 2012 Aug 13. J Clin Oncol. 2012. PMID: 22891270
-
Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.Am J Med Sci. 2018 Apr;355(4):350-356. doi: 10.1016/j.amjms.2017.12.003. Epub 2017 Dec 9. Am J Med Sci. 2018. PMID: 29661348
-
Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.Tumour Biol. 2016 Jan;37(1):619-25. doi: 10.1007/s13277-015-3776-5. Epub 2015 Aug 4. Tumour Biol. 2016. PMID: 26240025
-
Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.Am J Kidney Dis. 2005 Aug;46(2):270-7. doi: 10.1053/j.ajkd.2005.05.010. Am J Kidney Dis. 2005. PMID: 16112045 Review.
-
[Prognostic importance of lactate dehydrogenase (LDH) in oncology].Orv Hetil. 2017 Dec;158(50):1977-1988. doi: 10.1556/650.2017.30890. Orv Hetil. 2017. PMID: 29226713 Review. Hungarian.
Cited by
-
Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study.Aging Dis. 2020 Oct 1;11(5):1069-1081. doi: 10.14336/AD.2020.0630. eCollection 2020 Oct. Aging Dis. 2020. PMID: 33014523 Free PMC article.
-
MAGE genes: Prognostic indicators in AL amyloidosis patients.J Cell Mol Med. 2019 Aug;23(8):5672-5678. doi: 10.1111/jcmm.14475. Epub 2019 Jun 20. J Cell Mol Med. 2019. PMID: 31222935 Free PMC article.
-
Serum lactate dehydrogenase as a prognostic marker for 90-day mortality in connective tissue disease patients receiving glucocorticoids and hospitalized with pneumonia: a cohort study.Sci Rep. 2025 May 14;15(1):16806. doi: 10.1038/s41598-025-01721-9. Sci Rep. 2025. PMID: 40369099 Free PMC article.
-
Pre-and Post-Transplant Serum Lactate Dehydrogenase Levels as a Predictive Marker for Patient Survival and Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients.Rep Biochem Mol Biol. 2021 Jul;10(2):204-215. doi: 10.52547/rbmb.10.2.204. Rep Biochem Mol Biol. 2021. PMID: 34604410 Free PMC article.
-
Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study.Life (Basel). 2020 Oct 18;10(10):247. doi: 10.3390/life10100247. Life (Basel). 2020. PMID: 33081052 Free PMC article.
References
-
- Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schonland SO. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33:1371–1378. - PubMed
-
- Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–2325. - PubMed
-
- Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic dehydrogenase and cancer: an overview. Frontiers in bioscience. 2015;20:1234–1249. - PubMed
-
- Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989;74:1108–1111. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical